GlassScriptPhysician profile
Lora Mchale
NPI 1144432311
$2,471.57
in general payments reported to CMS, 2019-2025
28 companies · $620 in 2025
The $620 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $427 · 2022: $623 · 2023: $422 · 2024: $380 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $491.92 | 2021-2025 | |
| Novo Nordisk INC | $406.71 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $288.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $207.64 | 2021-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Amgen INC. | $165.50 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $141.00 | 2021-2022 | |
| Exact Sciences Corporation | $130.83 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $84.14 | 2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.56 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $61.90 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $52.32 | 2023-2024 | Spravato |
| Grifols USA, LLC | $45.75 | 2021-2023 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $44.10 | 2021-2022 | |
| Corcept Therapeutics | $36.55 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $30.41 | 2022-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $28.89 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.11 | 2024 | |
| Genentech USA, INC. | $18.90 | 2021 | |
| Seqirus USA INC | $17.00 | 2024 | Flucelvax, Fluad |
| Watermark Medical, INC. | $15.62 | 2024 | |
| Eisai INC. | $15.17 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.73 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.32 | 2025 | Caplyta |
| Irhythm Technologies, INC. | $14.01 | 2021 | |
| Cranial Technologies, INC | $14.00 | 2022 | |
| Cequr Corporation | $12.56 | 2022 | |
| Medtronic, INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Mchale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.